EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis

Olga Lucía Fernández, Mariana Rosales-Chilama, Andrea Sánchez-Hidalgo, Paola Gómez, David Esteban Rebellón-Sánchez, Ivo B Regli, Míriam Díaz-Varela, Fabienne Tacchini-Cottier, Nancy Gore Saravia iD

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0012156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Olga Lucía Fernández und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia. Hauptthemen laut MEDLINE: Leishmaniasis, Cutaneous, Meglumine Antimoniate, Mice, Inbred BALB C, Antiprotozoal Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, NIAID NIH HHS, United States National Institute of Allergy And Infectious Diseases of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The multifactorial basis of therapeutic response can obscure the relation between antimicrobial drug susceptibility and clinical outcome. To discern the relationship between parasite susceptibility to meglumine antimoniate (SbV) and therapeutic outcome of cutaneous leishmaniasis, risk factors for treatment failure were considered in evaluating this relationship in ninety-one cutaneous leishmaniasis patients and corresponding clinical strains of Leishmania ( Viannia ) panamensis . Parasite susceptibility to 32 μg SbV/mL (plasma C max ) was evaluated in primary human macrophages, PBMCs, and U937 macrophages. Early parasitological response to treatment was determined in lesions of a subgroup of patients, and pathogenicity of Sb-resistant and sensitive clinical strains was compared in BALB/c mice. Parasite survival in cell models and patient lesions was determined by qRT-PCR of Leishmania 7SLRNA transcript. Parasite loads in BALB/c mice were quantified by limiting dilution analysis. The disparate Sb-susceptibility of parasite subpopulations distinguished by isoenzyme profiles (zymodemes) was manifest in all cell models. Notably, Sb-resistance defined by parasite survival, was most effectively discerned in U937 macrophages compared with primary human host cells, significantly higher among strains from patients who failed treatment than cured and, significantly associated with treatment failure. Each unit increase in transformed survival rate corresponded to a 10.6-fold rise in the odds of treatment failure. Furthermore, treatment failure was significantly associated with naturally Sb-resistant zymodeme 2.3 strains, which also produced larger lesions and parasite burdens in BALB/c mice than Sb-sensitive zymodeme 2.2 strains. The confounding effect of host risk factors for treatment failure in discerning this association was evidenced in comparing strains from patients with and without the defined risk factors for treatment failure. These results establish the association of natural resistance to meglumine antimoniate with treatment failure, the importance of host risk factors in evaluating drug susceptibility and treatment outcome, and the clinical and epidemiological relevance of natural Sb-resistance in L . ( V .) panamensis subpopulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, CutaneousMeglumine AntimoniateMice, Inbred BALB CAntiprotozoal AgentsTreatment FailureDrug ResistanceMeglumineOrganometallic CompoundsMacrophagesAnimalsHumansFemaleMiceMaleLeishmania guyanensisAdultMiddle AgedYoung AdultParasite LoadAdolescent

Substanzen

Meglumine AntimoniateAntiprotozoal AgentsMeglumineOrganometallic Compounds

Autor:innen und Institutionen

  • Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia.
  • Universidad Icesi, Cali, Colombia.
  • Fundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Cali, Colombia.
  • Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.

ORCID-Profile: Nancy Gore Saravia

Förderung

  • FIC NIH HHS
  • NIAID NIH HHS
  • United States National Institute of Allergy And Infectious Diseases of the National Institutes of Health
  • Swiss programme for International Research by Scientific Investigation Teams
  • Ministry of Science, Technology, and Innovation of Colombia
  • Global Infectious Research Training Program of the Fogarty International Center of the U.S. National Institutes of Health

Zitieren

APA

Fernández, O. L., Rosales-Chilama, M., Sánchez-Hidalgo, A., Gómez, P., Rebellón-Sánchez, D. E., Regli, I. B., Díaz-Varela, M., Tacchini-Cottier, F., & Saravia, N. G. (2024). Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012156

Vancouver

Fernández OL, Rosales-Chilama M, Sánchez-Hidalgo A, Gómez P, Rebellón-Sánchez DE, Regli IB, et al. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012156

BibTeX
@article{Fernndez2024,
  author = {Fernández, Olga Lucía and Rosales-Chilama, Mariana and Sánchez-Hidalgo, Andrea and Gómez, Paola and Rebellón-Sánchez, David Esteban and Regli, Ivo B and Díaz-Varela, Míriam and Tacchini-Cottier, Fabienne and Saravia, Nancy Gore},
  title = {Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0012156}
}
Kostenlos starten →